RUSH ENTERPRISES INC \TX\ — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that RUSH ENTERPRISES INC \TX\ filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.43B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.80B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.93B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $7.10B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $5.13B | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $1.27B | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $1.18B | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $1.00B | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $1.29B | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $1.32B | Feb 24, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.06B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.45B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.57B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $6.78B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $4.88B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $4.50B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $5.56B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $5.27B | Feb 24, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $2.99B | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $2.64B | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $3.36B | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $3.20B | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $2.24B | Feb 29, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.46B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.53B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.59B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.49B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $1.09B | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $236.18M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $212.45M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $192.33M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $234.50M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $234.44M | Feb 24, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $263.78M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $304.15M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $347.06M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $391.38M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $241.42M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $41.03M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $33.94M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $16.82M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $23.11M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $23.75M | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $393.76M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $468.09M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $512.38M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $506.11M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $309.04M | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | $53.54M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $42.87M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $23.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $35.20M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $39.42M | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2014 | $2.00M | Mar 1, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $996.18M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $995.59M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.02B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $927.84M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $731.34M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $665.26M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $753.75M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $705.23M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $631.05M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $587.78M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $861.84M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $619.55M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $295.71M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $294.40M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $422.35M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $762.98M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $421.27M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $215.36M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $152.74M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $521.17M | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $399.83M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $433.05M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $368.88M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $243.06M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $167.18M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $136.20M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $293.49M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $238.26M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $209.92M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $196.97M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.43B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $4.62B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $4.36B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $3.82B | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $3.12B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $2.99B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $3.41B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $3.20B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $2.89B | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $2.60B | Feb 25, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.20B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $2.14B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.87B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.74B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.47B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.27B | Feb 24, 2022 |
| FY2021 | Dec 31, 2019 | $1.16B | Feb 24, 2022 |
| FY2021 | Dec 31, 2018 | $1.07B | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $1.04B | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $862.83M | Feb 26, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $441.62M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $427.49M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $420.71M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $416.36M | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | $370.33M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $292.14M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $292.14M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $291.39M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $291.39M | Feb 26, 2020 |
| FY2018 | Dec 31, 2016 | $290.19M | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.90B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.45B | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $1.38B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.03B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $831.85M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.07B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $942.29M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $812.56M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $640.43M | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $212.65M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $228.13M | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $183.73M | Feb 24, 2025 |
| FY2023 | Dec 31, 2022 | $201.04M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $148.15M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $312.05M | Feb 23, 2023 |
| FY2022 | Dec 31, 2019 | $181.62M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $131.73M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $124.54M | Feb 24, 2021 |
| FY2019 | Dec 31, 2016 | $82.03M | Feb 26, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $274.80M | Feb 25, 2026 |
| FY2024 | Dec 31, 2024 | $408.44M | Feb 24, 2025 |
| FY2023 | Dec 31, 2023 | $414.00M | Feb 23, 2024 |
| FY2022 | Dec 31, 2022 | $275.43M | Feb 23, 2023 |
| FY2021 | Dec 31, 2021 | $334.93M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | $529.65M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $627.68M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $601.17M | Feb 26, 2020 |
| FY2018 | Dec 31, 2017 | $611.53M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $603.22M | Mar 1, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 4 | Feb 24, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 23, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 24, 2021 |